Interní Med. 2005; 7(4): 182-185

Oral anticoagulant therapy

MUDr. Petr Kessler1,2
1 Oddělení hematologie a transfuziologie, Nemocnice Pelhřimov, p.o
2 Odddělení hematologie a transfuziologie, Nemocnice Pelhřimov, p.o

Warfarin is widely used in prophylaxis and treatment of thrombosis. Mechanism of it’s action is very complex, the dose – response relationship is hard to predict. The risk of bleeding associated with its use is substantial. This risk may be decreased by careful monitoring, optimalization of INR target range and by avoidance of significant drug interactions. Optimal duration of treatment in an individual patient with venous thromboembolism may be prescribed by using recurrence risk assessment.

Keywords: Key words: warfarin, drug interactions, atrial fibrillation, venous thromboembolism.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kessler P. Oral anticoagulant therapy. Interní Med. 2005;7(4):182-185.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hemker HC, Jie KSG. Proteins induced by vitamin K absence (PIVKAs): effect of coumarins on circulating clotting factors. In: L. Poller, J. Hirsh: Oral anticoagulants. Arnold, London, 1996.
    2. Linder MW, Looney S, Adams JE, et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis. 2002 Dec; 14 (3): 227-232. Go to original source... Go to PubMed...
    3. Palkimas Jr. MP, Skinner HM, Gandhi PJ, Gardner AJ. Polymorphism induced sensitivity to warfarin: a review of the literature. J Thromb Thrombolysis. 2003 Jun; 15 (3): 205-212. Go to original source... Go to PubMed...
    4. D'Andrea G, D'ambrosio RL, Di Perna P, et al. A polymorphism in VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood. 2005 Jan 15; 105 (2): 645-649. Go to original source... Go to PubMed...
    5. Widimský J, Chrobák L, Přerovský I, et al. Současný stav a perspektivy perorální antikoagulační léčby. Praktický lékař, 67, 1987 (10); 67: 390-393.
    6. White RH, McCurdy SA, von Marensdorff H, Woodruff DE Jr, Leftgoff L. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study. Ann Intern Med 1989 Nov 1; 111 (9): 730-737. Go to original source... Go to PubMed...
    7. Ansell JE, Patel N, Ostrovsky D, Nozzolillo E, Peterson AM, Fish L. Long-term patient self-management of oral anticoagulation. Arch Intern Med 1995 Nov 13; 155 (20): 2185-2189. Go to original source...
    8. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med 2000 Nov 7; 133 (9): 687-695. Go to original source... Go to PubMed...
    9. Salem DN, Stein PD, Amin Al-Ahmad, et al. Antithrombotic Therapy in Valvular Heart Disease - Native and Prosthetic. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy CHEST 2004; 126: 457S-482S. Go to original source... Go to PubMed...
    10. Herlitz J, Holm J, Peterson M, et al. For the LoWASA study group. Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. Eur Heart J. 2004 Feb; 25 (3): 232-239. Go to original source... Go to PubMed...
    11. Crowther MA, Clase CM, Margetts PJ, et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol 2002 Sep; 13 (9): 2331-2337. Go to original source... Go to PubMed...
    12. Boraks P, Seale J, Price J, et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol. 1998 Jun; 101 (3): 483-486. Go to original source... Go to PubMed...
    13. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994 Apr 9; 343 (8902): 886-889. Go to original source... Go to PubMed...
    14. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. N Engl J Med. 2003 Apr 10; 348 (15): 1425-1434. Go to original source... Go to PubMed...
    15. Atrial Fibrillation Investigators: Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation. Analysis of Pooled Data From Five Randomized Controlled Trials. Arch. Intern. Med. 1994; 154: 1449-1457. Go to original source... Go to PubMed...
    16. Schulman S, Rhedin AS, Lindmarker P, et al. A Comparison of six weeks with six months of oral anticoagulant therapy after first episode of venous thromboembolism. New Engl. J. Med. 1995; 332: 1661-1665. Go to original source... Go to PubMed...
    17. Piovella F, Crippa L, Barone M, et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica. 2002; 87: 515-522. Go to PubMed...
    18. Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA. 2003; 290: 1071-1074. Go to original source... Go to PubMed...
    19. Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic Complications of Anticoagulant treatment. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy CHEST 2004; 126: 287S-310S. Go to original source... Go to PubMed...
    20. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Annals of intern. med. 1994; 121 (9): 676-683. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.